# A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

> **NCT05794477** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 132 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** Adebrelimab
- **BIOLOGICAL:** SHR-1802
- **DRUG:** Carboplatin/Cisplatin
- **DRUG:** Paclitaxel/Nab-Paclitaxel/Pemetrexed

## Key facts

- **NCT ID:** NCT05794477
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-28
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05794477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05794477, "A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05794477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*